EGFR and non-small cell lung carcinoma: The addition of pembrolizumab to chemotherapy in patients with TKI‐resistant, EGFR‐mutated metastatic nonsquamous NSCLC resulted in a reduction in both PFS and OS compared to pemetrexed and chemotherapy alone.